Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.59+0.00 (+0.29%)
Close on Nov 11, 2026Market cap $164.37MP/E –Yield –
Humacyte operating margin
Operating margin is operating income as a percentage of revenue.
Humacyte's operating margin for the twelve months ending Sep 30, 2026 was -4602.9%. For fiscal 2025 it was -5306.0%.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5306.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -2287.8% | +951.2 |
| Q2 FY2026 | Jun 30, 2026 | -6649.3% | +3226.8 |
| Q1 FY2026 | Mar 31, 2026 | -5845.5% | −1361.1 |
| Q4 FY2025 | Dec 31, 2025 | -6603.0% | +1921.1 |
| Q3 FY2025 | Sep 30, 2025 | -3239.0% | −1355.8 |
| Q2 FY2025 | Jun 30, 2025 | -9876.1% | – |
| Q1 FY2025 | Mar 31, 2025 | -4484.3% | – |
| Q3 FY2021 | Sep 30, 2021 | -8524.1% | – |
| Q3 FY2020 | Sep 30, 2020 | -1883.3% | – |
See a number that looks wrong?